Lenard Conradi

Lenard Conradi

Auto-generated profile, based on publicly available information

Lenard Conradi

Department of Cardiovascular Surgery, University Heart Center Hamburg, Hamburg, Germany

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 October 2010 in Clinical Research in Cardiology
Verified
Journal Article
Closed access
PDF file
LCLenard Conradi
Lenard Conradi
MSMoritz Seiffert
Moritz Seiffert
OFOlaf Franzen
Olaf Franzen
SBStephan Baldus
Stephan Baldus
JSJohannes Schirmer
Johannes Schirmer
HTHendrik Treede
Hendrik Treede

10 February 2013 in European Journal of Cardio-Thoracic Surgery
Verified
Journal Article
Open access
PDF file
LCLenard Conradi
Lenard Conradi
HTHendrik Treede
Hendrik Treede
VRVolker Rudolph
Volker Rudolph
PGPaul Graumüller
Paul Graumüller
ELEdith Lubos
Edith Lubos
HRHermann Reichenspurner
Hermann Reichenspurner
Corrective surgery for secondary mitral regurgitation (MR) by restrictive annuloplasty has proven beneficial in that it improves New York Heart Association (NYHA) functional class and induces reverse left ventricular remodelling. However, proof of a survival benefit for these patients is still pending. Percutaneous techniques of mitral valve repair (MVR) have become a viable treatment alternative for selected high-risk patients with severe secondary MR. We retrospectively analysed our prospective hospital database of patients with severe secondary MR undergoing either surgical MVR or percutaneous treatment using the MitraClip device. Patient characteristics and 6-month clinical and effectiveness outcomes are reported. From March 2002 through June 2010, 76 patients with secondary MR underwent isolated surgical MVR, while 95 were treated using the MitraClip device at our centre. Patients undergoing MitraClip treatment were significantly older (mean 72.8 ± 8.2 vs 64.5 ± 11.4 years, P < 0.001), had a lower left ventricular ejection fraction (mean 36.2 ± 12.5 vs 42.1 ± 16.2%, P = 0.014) and were generally more high risk, with a significantly higher mean logistic EuroSCORE I compared with surgical candidates (33.7 ± 18.7 vs 10.1 ± 8.7%, P < 0.001). Procedural success was 98.7 (75 of 76) for MVR and 95.8% (91 of 95) for MitraClip treatment (P = 0.383). Thirty-day mortality was 4.2 (4 of 95) and 2.6% (2 of 76; P = 0.557), and the mean grade of residual MR was 1.4 ± 0.8 and 0.2 ± 0.4 (P < 0.001) after MitraClip treatment and surgical MVR, respectively. Six-month survival rates after adjustment for baseline differences were not significantly different in the respective groups (P = 0.642). In our experience, characteristics and risk factors of patients with severe secondary MR undergoing surgery differ significantly from those considered for percutaneous therapy. Surgery was more effective compared with MitraClip in reducing MR. However, a large proportion of patients benefits from percutaneous intervention with sustained MR Grade <2+ and improvement in NYHA functional class at 6 months. MitraClip therapy seems to be an adequate alternative to surgery, especially for elderly patients with reduced left ventricular function and relevant comorbidities. Assessment, treatment and postprocedural care of patients by an interdisciplinary team are of paramount importance for clinical success.

1 January 2012 in The Journal of Thoracic and Cardiovascular Surgery
Verified
Journal Article
Closed access
LCLenard Conradi
Lenard Conradi
MSMoritz Seiffert
Moritz Seiffert
HTHendrik Treede
Hendrik Treede
MSMiriam Silaschi
Miriam Silaschi
SBStephan Baldus
Stephan Baldus
HRHermann Reichenspurner
Hermann Reichenspurner

1 December 2015 in The Journal of Thoracic and Cardiovascular Surgery
Verified
Journal Article
Closed access
LCLenard Conradi
Lenard Conradi
MSMiriam Silaschi
Miriam Silaschi
MSMoritz Seiffert
Moritz Seiffert
ELEdith Lubos
Edith Lubos
SBStefan Blankenberg
Stefan Blankenberg
HTHendrik Treede
Hendrik Treede

11 December 2013 in European Journal of Cardio-Thoracic Surgery
Verified
Journal Article
Open access
PDF file
LCLenard Conradi
Lenard Conradi
MSMoritz Seiffert
Moritz Seiffert
JSJohannes Schirmer
Johannes Schirmer
DKDietmar Koschyk
Dietmar Koschyk
SBStefan Blankenberg
Stefan Blankenberg
HTHendrik Treede
Hendrik Treede
Currently, preimplant balloon aortic valvuloplasty (BAV) is considered a prerequisite for successful subsequent transapical transcatheter aortic valve implantation (TA-TAVI) using balloon-expandable devices. However, cerebral embolization has been shown to originate at least in part from BAV procedures. Omitting BAV may therefore reduce neurological events after TAVI and facilitate the procedure while yielding non-inferior haemodynamic and clinical outcomes. From May 2011 through December 2012, a total of 50 consecutive patients were treated by TA-TAVI without preimplant BAV (TA-TAVI−BAV, study group) using the Edwards Sapien XT device (54% male, age 78 ± 8 years, logistic European System for Cardiac Operative Risk Evaluation I 21 ± 14%). Data were prospectively entered into a dedicated database, retrospectively analysed and compared with a consecutive series of conventional TA-TAVI using the same device (control group, n = 50). Reporting of data followed Valve Academic Research Consortium definitions. Overall device success rate was 94% (47/50) and 86% (43/50) in study and control groups, respectively (P = 0.32). Procedure time was similar in the study group compared with the control group (88 ± 31 vs 91 ± 25 min, P = 0.60), while significantly less contrast was used (138 ± 68 vs 183 ± 78 ml, P < 0.001). Post-procedural peak and mean transvalvular gradients were 16 ± 7 and 8 ± 3 mmHg, respectively, in the study group with similar values in the control group (19 ± 9 and 9 ± 5 mmHg, P = 0.08 and P = 0.09, respectively). Residual paravalvular leakage (PVL) grade 2 was present in 2 and 8% in study and control groups, respectively (P = 0.36), with no PVL >grade 2 in any patient. Rates of 30-day mortality and periprocedural stroke were 4 and 10% (P = 0.44) and 2 and 6% (P = 0.62), respectively. TA-TAVI−BAV is feasible and safe and has become our default technique for patients allocated to TA-TAVI with balloon-expandable devices. This approach resulted in less contrast agent used and facilitated the procedure without compromising valve performance. Possible beneficial effects of this approach on the incidence of cerebrovascular events, other periprocedural complications or haemodynamic valve performance need to be verified in larger patient numbers before general recommendations can be made.

7 October 2015 in The Thoracic and Cardiovascular Surgeon
Verified
Journal Article
Closed access
PDF file
HTHendrik Treede
Hendrik Treede
BRBeate Reiter
Beate Reiter
USUlrich Schaefer
Ulrich Schaefer
SBStefan Blankenberg
Stefan Blankenberg
HRHermann Reichenspurner
Hermann Reichenspurner
LCLenard Conradi
Lenard Conradi
Objectives Biological prostheses for surgical aortic valve replacement (sAVR) are increasingly being considered in patients < 60 years of age. Likely, preserving the option of performing a transcatheter valve-in-valve (ViV) procedure in cases of structural valve deterioration has contributed to this development. We assessed the use pattern in sAVR over an 11-year period. Methods From 2002 through 2012, a total of 3,172 patients underwent sAVR at our center. Results Mean age was 70.4 ± 10.6 years and mortality was 1.9%. From 2002 to 2012, mean manufacturer given valve size increased from 22.8 ± 1.7 to 23.9 ± 2.0 mm (p < 0.001). Mean true internal diameter and effective orifice area increased from 19.6 to 20.3 mm (p = 0.027) and 1.41 to 1.56 cm2 (p < 0.001), respectively. Use of mechanical valves decreased from 10.9 to 1.8% (p < 0.001), and patients were younger in 2012 than in 2002 (52.8 ± 16.5 vs. 41.0 ± 14.3 years; p = 0.028). Conclusion Profound change of use pattern in sAVR was observed as indication for biological prostheses became more liberal. Larger prostheses were implanted during the observational period. Especially in younger patients, optimal sizing is essential to preserve the option for subsequent ViV procedures. * Both the authors contributed equally to this work.